Inhibition of inducible nitric oxide synthase prevents mitochondrial damage and improves survival of steatotic partial liver grafts

Transplantation

Volumn 89, Issue 3, 2010, Pages 291-298

  He, Songqing ^a,b   Rehman, Hasibur ^a   Wright, Gary L ^a   Zhong, Zhi ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

1400W; Fatty liver; INOS; Mitochondria; Partial liver transplantation

Indexed keywords

3 NITROTYROSINE; ALANINE AMINOTRANSFERASE; BILIRUBIN; CYTOCHROME C OXIDASE; CYTOCHROME C OXIDASE IV; FRUCTOSE; INDUCIBLE NITRIC OXIDE SYNTHASE; N [3 (AMINOMETHYL)BENZYL]ACETAMIDINE; NITRATE; NITRITE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE BETA; REACTIVE NITROGEN SPECIES; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE 3; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; ENZYME INHIBITION; FATTY LIVER; GRAFT DYSFUNCTION; GRAFT SURVIVAL; LIPID DIET; LIPID LIVER LEVEL; LIVER MITOCHONDRION; LIVER TRANSPLANTATION; LOW FAT DIET; MALE; MITOCHONDRIAL RESPIRATION; MITOCHONDRIAL TOXICITY; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SUGAR INTAKE; UPREGULATION;

ALANINE TRANSAMINASE; ANIMALS; BILIRUBIN; ENZYME INHIBITORS; FATTY LIVER; GRAFT SURVIVAL; IMMUNOHISTOCHEMISTRY; LIVER; LIVER TRANSPLANTATION; MALE; MITOCHONDRIA; NITRIC OXIDE SYNTHASE TYPE II; RATS; RATS, INBRED LEW; SUTURES; TRIGLYCERIDES; TYROSINE;

EID: 76649124268     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181c99185     Document Type: Article

References (57)

1. Hashimoto K, Miller C. The use of marginal grafts in liver transplantation. J Hepatobiliary Pancreat Surg 2008; 15: 92.
2. Renz JF, Emond JC, Yersiz H, et al. Split-liver transplantation in the United States: Outcomes of a national survey. Ann Surg 2004; 239: 172.
3. Strong RW. Living-donor liver transplantation: An overview. J Hepa-tobiliary Pancreat Surg 2006; 13: 370.
4. Sugawara Y, Makuuchi M, Takayama T, et al. Small-for-size grafts in living-related liver transplantation. J Am Coll Surg 2001; 192: 510.
5. KiuchiT, KasaharaM, UryuharaK, et al. Impact ofgraft size mismatching on graft prognosis in liver transplantation from living donors. Transplantation 1999; 67: 321.
6. Behrns KE, Tsiotos GG, DeSouza NF, et al. Hepatic steatosis as a potential risk factor for major hepatic resection. J Gastrointest Surg 1998; 2: 292.
7. Mittler J, Pascher A, Neuhaus P, et al. The utility of extended criteria donor organs in severely ill liver transplant recipients. Transplantation 2008; 86: 895.
8. Nocito A, El-Badry AM, Clavien PA. When is steatosis too much for transplantation? J Hepatol 2006; 45: 494.
9. Urena MA, Moreno GE, Romero CJ, et al. An approach to the rational use of steatotic donor livers in liver transplantation. Hepatogastroenter-ology 1999; 46: 1164.
10. Sun Z, Klein AS, Radaeva S, et al. In vitro interleukin-6 treatment prevents mortality associated with fatty liver transplants in rats. Gas-troenterology 2003; 125: 125.
11. Marsman WA, Wiesner RH, Rodrigues L, et al. Use of fatty donor liver is associated with diminished early patient and graft survival. Transplantation 1997; 62: 1246.
12. Strasberg SM, Howard TK, Molmenti EP, et al. Selecting the donor liver: Risk factors for poor function after orthotopic liver transplantation. Hepatology 1994; 20: 829.
13. Rinella ME, Alonso E, Rao S, et al. Body mass index as a predictor of hepatic steatosis in living liver donors. Liver Transpl 2001; 7: 409.
14. Garcia Urena MA, Colina Ruiz-Delgado F, Moreno GE, et al. Hepatic steatosis in liver transplant donors: Common feature of donor population? World J Surg 1998; 22: 837.
15. Man K, Zhao Y, Xu A, et al. Fat-derived hormone adiponectin combined with FTY720 significantly improves small-for-size fatty liver graft survival. Am J Transplant 2006; 6: 467.
16. Zhong Z, Connor HD, Froh M, et al. Polyphenols from Camellia sine-nesis prevent primary graft failure after transplantation of ethanol-induced fatty livers from rats. Free Radic Biol Med 2004; 36: 1248.
17. Zhong Z, Connor HD, Froh M, et al. Free radical-dependent dysfunction of small-for-size rat liver grafts: Prevention by plant polyphenols. Gastroenterology 2005; 129: 652.
18. Shah V, Kamath PS. Nitric oxide in liver transplantation: Pathobiology and clinical implications. Liver Transpl 2003; 9: 1.
19. Anggard E. Nitric oxide: Mediator, murderer, and medicine. Lancet 1994; 343: 1199.
20. Chen T, Zamora R, Zuckerbraun B, et al. Role of nitric oxide in liver injury. Curr Mol Med 2003; 3: 519.
21. Theruvath TP, Zhong Z, Currin RT, et al. Endothelial nitric oxide syn-thase protects transplanted mouse livers against storage/reperfusion injury: Roleofvasodilatory and innate immunity pathways. Transplant Proc 2006; 38: 3351.
22. Lang JD Jr, Teng X, Chumley P, et al. Inhaled NO accelerates restoration of liver function in adults following orthotopic liver transplantation. J Clin Invest 2007; 117: 2583.
23. Carnovale CE, Scapini C, Alvarez ML, et al. Nitric oxide release and enhancement of lipid peroxidation in regenerating rat liver. J Hepatol 2000; 32: 798.
24. Koeppel TA, Mihaljevic N, Kraenzlin B, et al. Enhanced iNOS gene expression in the steatotic rat liver after normothermic ischemia. Eur Surg Res 2007; 39: 303.
25. Zhong Z, Theruvath TP, Currin RT, et al. NIM811, a mitochondrial permeability transition inhibitor, prevents mitochondrial depolarization in small-for-size rat liver grafts. Am J Transplant 2007; 7: 1103.
26. Zhong Z, Schwabe RF, Kai Y, et al. Liver regeneration is suppressed in small-for-size liver grafts after transplantation: involvement of JNK, cyclin D1 and defective energy supply. Transplantation 2006; 82: 241.
27. Rehman H, Connor HD, Ramshesh VK, et al. Ischemic preconditioning prevents free radical production and mitochondrial depolarization in small-for-size rat liver grafts. Transplantation 2008; 85: 1322.
28. Bray GA, Nielsen SJ, Popkin BM. Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. Am J Clin Nutr 2004; 79: 537.
29. Basciano H, Federico L, Adeli K. Fructose, insulin resistance, and metabolic dyslipidemia. Nutr Metab (Lond) 2005; 2: 5.
30. Rela M, Vougas V, Muiesan P, et al. Split liver transplantation: King's College Hospital experience. Ann Surg 1998; 227: 282.
31. McCormackL, PetrowskyH, Jochum W, et al. Hepatic steatosisisarisk factor for postoperative complications after major hepatectomy: A matched case-control study. Ann Surg 2007; 245: 923.
32. Selzner M, Clavien PA. Fatty liver in liver transplantation and surgery. Semin Liver Dis 2001; 21: 105.
33. Trotter JF. Thin chance for fat people (to become living donors). Liver Transpl 2001; 7: 415.
34. Ye S, Han B, Dong J. Reduced-size orthotopic liver transplantation with different grade steatotic grafts in rats.Chin Med J(Engl) 2003; 116: 1141.
35. Morioka D, Kubota T, Sekido H, et al. Prostaglandin E1 improved the function of transplanted fatty liver in a rat reduced-size-liver transplantation model under conditions of permissible cold preservation. Liver Transpl 2003; 9: 79.
36. Teli MR, James OF, Burt AD, et al. The natural history of nonalcoholic fatty liver: A follow-up study. Hepatology 1995; 22: 1714.
37. Ackerman Z, Oron-Herman M, Grozovski M, et al. Fructose-induced fatty liver disease: Hepatic effects of blood pressure and plasma triglyc-eride reduction. Hypertension 2005; 45: 1012.
38. Koteish A, Diehl AM. Animal models of steatosis. Semin Liver Dis 2001; 21: 89.
39. UrakamiH, AbeY, Grisham MB. Roleofreactive metabolitesofoxygen and nitrogen in partial liver transplantation: Lessons learned from reduced-size liver ischaemia and reperfusion injury. Clin Exp Pharmacol Physiol 2007; 34: 912.
40. Rai RM, Lee FY, Rosen A, et al. Impaired liver regeneration in inducible nitric oxide synthasedeficient mice. Proc Natl Acad Sci USA 1998; 95: 13829.
41. Chao JI, Kuo PC. Role of p53 and p38 MAP kinase in nitric oxide-induced G2/M arrest and apoptosis in the human lung carcinoma cells. Carcinogenesis 2004; 25: 645.
42. Isobe M, Katsuramaki T, Hirata K, et al. Beneficial effects of inducible nitric oxide synthase inhibitor on reperfusion injury in the pig liver. Transplantation 1999; 68: 803.
43. Kleinert H, Boissel J-P, Schwarz PM, et al. Regulation of the expression of nitric oxide synthase isoforms. In: Ignarro LJ, ed. Nitric oxide, biology and pathobiology. San Diego, Academic Press 2000, p 105.
44. Diehl AM. Tumor necrosis factor and its potential role in insulin resistance and nonalcoholic fatty liver disease. Clin Liver Dis 2004; 8: 619.
45. Zhong Z, Connor H, Stachlewitz RF, et al. Role of free radicals in primary non-function of marginal fatty grafts from rats treated acutely with ethanol. Mol Pharmacol 1997; 52: 912.
46. Byrne CD, Olufadi R, Bruce KD, et al. Metabolic disturbances in nonalcoholic fatty liver disease. Clin Sci 2009; 116: 539.
47. Theruvath TP, Zhong Z, Pediaditakis P, et al. Minocycline and N-methyl-4-isoleucine cyclosporin (NIM811) mitigate storage/reper-fusion injury after rat liver transplantation through suppression of the mitochondrial permeability transition. Hepatology 2008; 47: 236.
48. Selzner N, Selzner M, Jochum W, et al. Mouse livers with macrosteato-sis are more susceptible to normothermic ischemic injury than those with microsteatosis. J Hepatol 2006; 44: 694.
49. Reichert SA, Kim-Han JS, Dugan LL. The mitochondrial permeability transition pore and nitric oxide synthase mediate early mitochondrial depolarization in astrocytes during oxygen-glucose deprivation. J Neu-rosci 2001; 21: 6608.
50. Kim JS, Ohshima S, Pediaditakis P, et al. Nitric oxide protects hepato-cytes against mitochondrial permeability transition-induced reperfu-sion injury. Hepatology 2004; 39: 1533.
51. Dedkova EN, Blatter LA. Characteristics and function of cardiac mito-chondrial nitric oxide synthase. J Physiol 2009; 587(pt 4): 851.
52. West MB, Rokosh G, Obal D, et al. Cardiac myocyte-specific expression of inducible nitric oxide synthase protects against ischemia/reperfusion injury by preventing mitochondrial permeability transition. Circulation 2008; 118: 1970.
53. Escames G, Lopez LC, Tapias V, et al. Melatonin counteracts inducible mitochondrial nitric oxide synthase-dependent mitochondrial dysfunction in skeletal muscle of septic mice. J Pineal Res 2006; 40: 71.
54. Lopez LC, Escames G, Tapias V, et al. Identification of an inducible nitric oxide synthase in diaphragm mitochondria from septic mice: its relation with mitochondrial dysfunction and prevention by melatonin. Int J Biochem Cell Biol 2006; 38: 267.
55. Mantena SK, Vaughn DP, Andringa KK, et al. High fat diet induces dysregulation of hepatic oxygen gradients and mitochondrial function in vivo. Biochem J 2009; 417: 183.
56. Ren XY, Li YN, Qi JS, et al. Peroxynitrite-induced protein nitration contributes to liver mitochondrial damage in diabetic rats. J Diabetes Complications 2008; 22: 357.
57. Holohan C, Szegezdi E, Ritter T, et al. Cytokine-induced beta-cell ap-optosis is NO-dependent, mitochondria-mediated and inhibited by BCL-XL. J Cell Mol Med 2008; 12: 591.